rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    COYA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Coya Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

      HOUSTON, November 10, 2026--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces its financial results for the quarter ended September 30, 2026 and provides a corporate update.

      Nov 10Yahoo FinanceCOYA
      Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual NEALS Meeting
      Oct 28Yahoo FinanceCOYA
      Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference
      Oct 13Yahoo FinanceCOYA
      Coya Therapeutics stock reiterated at Buy by H.C. Wainwright on trial enrollment
      Oct 6Investing.comCOYA
      Coya completes enrollment in ALS trial, data due early Q2 2027
      Oct 5Investing.comCOYA
      Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
      Oct 5Yahoo FinanceCOYA
      Exosomes Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 100+ Leading Players Wheeling the Therapeutics Landscape
      Sep 29BarchartCOYA
      Coya Therapeutics stock maintained at Buy by H.C. Wainwright
      Sep 25Investing.comCOYA
      Coya Therapeutics Advances COYA 302 ALS Phase 2/3 Trial

      Detailed price information for Coya Therapeutics Inc (COYA-Q) from The Globe and Mail including charting and trades.

      Sep 16The Globe and MailCOYA
      Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
      Sep 15Yahoo FinanceCOYA
      Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation

      HOUSTON, September 08, 2026--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today announced the publication of preclinical results for COYA 303 in the International Journal of Molecular Sciences. The article was published as part of the Special Issue, "The Roles of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Health and Disease," which highlights the expanding therapeutic app

      Sep 8Yahoo FinanceCOYA
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Medtronic Inc (MDT-N) from The Globe and Mail including charting and trades.

      Aug 25The Globe and MailCOYA
      H.C. Wainwright reiterates Coya Therapeutics stock rating at buy
      Aug 24Investing.comCOYA

      This is the newest page. Registered accounts read further back.